U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182708) titled 'High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC' on Sept. 05.
Brief Summary: This is a Phase II, single-arm, open-label, multicenter clinical study aimed at evaluating the efficacy and safety of Firmonertinib 160 mg combined with Bevacizumab as neoadjuvant therapy in patients with resectable stage II-IIIB Epidermal Growth Factor Receptor(EGFR)-mutated non-small cell lung cancer.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
NSCLC (Non-small Cell Lung Cancer)
EGFR Activating Mutation
Resectable Lung Non-Small Cell Carcinoma
Intervention:
DRUG: Firmonert...